Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Biguanides × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Genitourinary 1 CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 371 pembrolizumab 283 Prednisone 254 enzalutamide 246 Gemcitabine 236 Magnetic Resonance Spectroscopy 233 Radiotherapy 231 Nivolumab 221 Abiraterone Acetate 186 Cisplatin 179 Radiosurgery 174 Leuprolide 171 Sunitinib 155 Carboplatin 142 Specimen Handling 135 Androgen Antagonists 130 bicalutamide 125 Goserelin 125 Ipilimumab 116 Paclitaxel 115 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 109 apalutamide 105 Cyclophosphamide 101 Everolimus 99 Biopsy 96 Sorafenib 95 cabozantinib 94 Bevacizumab 91 abiraterone 90 atezolizumab 88

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02497638 2021-04-19

LIGAND

University Health Network, Toronto

Phase 2 Withdrawn

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡